Compounders Research Compare

Corbus Pharmaceuticals Holdings, Inc.(CRBP)

Biotechnology · Norwood, MA

$5.85-0.00 (-0.09%)

Delayed quote: Oct 6, 2026, 10:55 AM EDT

About Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

Norwood, MA

36 employees

www.corbuspharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Yuval Cohen

View full financials

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T14:56:26.875Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:56:26.875Z.

Quote observation: 2026-10-06T14:55:29.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 108,294,991
Total debt · period ending 2026-06-30: 4,264,000
Cash · period ending 2026-06-30: 23,370,000
TTM operating EBITDA · period ending 2026-06-30: -106,057,000

FMP input reference: 26be04fabca1f5abb96b6b094ab833c4d2e2f23bc88365d6eea621c26c981704

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CRBP EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

CRBP Competitors' EV/EBITDA Ratio

Corbus Pharmaceuticals Holdings, Inc.

Current

Market Cap

$108.29M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Cumberland Pharmaceuticals Inc.

Market Cap

$107.28M

EV/EBITDA Ratio

N/A

TTM Avg

20.46x

3Y Avg

22.62x

5Y Avg

53.44x

Immunic, Inc.

Market Cap

$107.34M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Black Diamond Therapeutics, Inc.

Market Cap

$107.44M

EV/EBITDA Ratio

N/A

TTM Avg

20.17x

3Y Avg

20.17x

5Y Avg

20.17x

Aardvark Therapeutics, Inc. Common Stock

Market Cap

$109.42M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Apyx Medical Corporation

Market Cap

$108.64M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Definitive Healthcare Corp.

Market Cap

$105.48M

EV/EBITDA Ratio

0.49x

TTM Avg

1.56x

3Y Avg

17.47x

5Y Avg

77.57x

BGM Group Ltd.

Market Cap

$111.14M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Foghorn Therapeutics Inc.

Market Cap

$112.19M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

The Joint Corp.

Market Cap

$102.00M

EV/EBITDA Ratio

25.90x

TTM Avg

52.21x

3Y Avg

97.08x

5Y Avg

75.85x

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Corbus Pharmaceuticals Holdings, Inc. (CRBP)	$108.29M	N/A	N/A	N/A	N/A
Cumberland Pharmaceuticals Inc. (CPIX)vs ›	$107.28M	N/A	20.46x	22.62x	53.44x
Immunic, Inc. (IMUX)vs ›	$107.34M	N/A	N/A	N/A	N/A
Black Diamond Therapeutics, Inc. (BDTX)vs ›	$107.44M	N/A	20.17x	20.17x	20.17x
Aardvark Therapeutics, Inc. Common Stock (AARD)vs ›	$109.42M	N/A	N/A	N/A	N/A
Apyx Medical Corporation (APYX)vs ›	$108.64M	N/A	N/A	N/A	N/A
Definitive Healthcare Corp. (DH)vs ›	$105.48M	0.49x	1.56x	17.47x	77.57x
BGM Group Ltd. (BGM)vs ›	$111.14M	N/A	N/A	N/A	N/A
Foghorn Therapeutics Inc. (FHTX)vs ›	$112.19M	N/A	N/A	N/A	N/A
The Joint Corp. (JYNT)vs ›	$102.00M	25.90x	52.21x	97.08x	75.85x

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics